Nephros Inc (NEPH)vsResMed Inc (RMD)
NEPH
Nephros Inc
$3.17
-9.69%
HEALTHCARE · Cap: $38.34M
RMD
ResMed Inc
$250.17
-0.25%
HEALTHCARE · Cap: $33.61B
Smart Verdict
WallStSmart Research — data-driven comparison
ResMed Inc generates 27182% more annual revenue ($5.65B vs $20.72M). RMD leads profitability with a 27.0% profit margin vs 8.4%. RMD trades at a lower P/E of 22.9x. RMD earns a higher WallStSmart Score of 67/100 (B-).
NEPH
Buy59
out of 100
Grade: C
RMD
Strong Buy67
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+11.8%
Fair Value
$4.58
Current Price
$3.17
$1.41 discount
Margin of Safety
-21.2%
Fair Value
$214.26
Current Price
$250.17
$35.91 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 36.2% year-over-year
Earnings expanding 450.0% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Strong operational efficiency at 20.2%
Strong operational efficiency at 30.9%
Safe zone — low bankruptcy risk
Every $100 of equity generates 23 in profit
Keeps 27 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Generating 1.6B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of 7.3% — below average capital efficiency
Weak financial health signals
Distress zone — elevated risk
2.4% earnings growth
Comparative Analysis Report
WallStSmart ResearchBull Case : NEPH
The strongest argument for NEPH centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 36.2% demonstrates continued momentum.
Bull Case : RMD
The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.0% and operating margin at 30.9%. PEG of 1.29 suggests the stock is reasonably priced for its growth.
Bear Case : NEPH
The primary concerns for NEPH are Market Cap, Return on Equity, Piotroski F-Score.
Bear Case : RMD
The primary concerns for RMD are EPS Growth.
Key Dynamics to Monitor
NEPH profiles as a hypergrowth stock while RMD is a mature play — different risk/reward profiles.
NEPH carries more volatility with a beta of 1.64 — expect wider price swings.
NEPH is growing revenue faster at 36.2% — sustainability is the question.
RMD generates stronger free cash flow (1.6B), providing more financial flexibility.
Bottom Line
RMD scores higher overall (67/100 vs 59/100), backed by strong 27.0% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Nephros Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Nephros, Inc., a commercial stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company is headquartered in South Orange, New Jersey.
ResMed Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?